Content area

|
|

Biologiske antireumatika til gravide og ammende kvinder eller mandlige partnere

Forfatter(e)

Karin Povlsen1, Kenneth Skov1, Lone Storgaard2 & Stig Ejdrup Andersen1

1) Klinisk Farmakologisk Enhed, Sjællands Universitetshospital, Roskilde, 2) Obstetrisk Klinik, Rigshospitalet

Ugeskr Læger 2021;183:V06200479

Reference: 
Ugeskr Læger 2020;182:V06200479
Blad nummer: 
Biological disease-modifying anti-rheumatic drugs for pregnant and lactating women or male partners

Karin Povlsen, Kenneth Skov, Lone Storgaard & Stig Ejdrup Andersen

Ugeskr Læger 2021;183:V06200479

Effective medical treatment of rheumatic diseases during pregnancy and lactation is important, but the evidence for use of biological disease-modifying anti-rheumatic drugs (bDMARDs) is sparse and recommendations conflicting, which we discuss in this review. While some tumour necrosis factor (TNF)-α inhibitors appear safe during pregnancy and lactation, the evidence for use of non-TNF-α inhibitors is still too sparse to exclude adverse pregnancy outcomes and harm to the lactating child. The limited evidence on paternal exposure indicates, that TNF-α inhibitors do not affect male fertility or harm offspring. For non-TNF-α inhibitors, the evidence is still insufficient to draw any conclusion.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Birger Kreutzfeldt | 16/09
1 Kommentar
af Thomas Korgaard Jensen | 15/09
1 Kommentar
af Jørgen Larsen | 15/09
12 kommentarer
af Morten Blomgren | 13/09
4 kommentarer
af Frederik Drejer Thrane | 13/09
1 Kommentar